Prediction of Critical Weight Loss During Radiation Treatment in Head and Neck Cancer Patients is Dependent on BMI

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2015 Nov 11

PMID 26553031

Citations 20

Authors

Simon Lonbro

Gry Bjerg Petersen

Jens Rikardt Andersen

Jorgen Johansen

Affiliations

Soon will be listed here.

Abstract

Purpose: The aims of the present study were to explore pre-treatment predictors of weight loss during radiation treatment only in head and neck cancer (HNSCC) patients and investigate the weight loss in patients with or without a feeding tube.

Methods: Retrospectively, weight change during curative radiotherapy was investigated in 476 consecutive HNSCC patients. Independent predictors were identified using multivariate regression analysis with weight loss below or above 5 % as the primary dependent variable.

Results: Baseline BMI, tumor site, and stage predicted weight loss above 5 %. The odds of weight loss above 5 % in patients with BMI >25 were 3.00 ± 0.64 times higher compared with patients with BMI <25 (p < 0.0001). Patients with pharyngeal, oral cavity, or supraglottic tumors had 3.12 ± 0.80 times higher odds of weight loss above 5 % compared with glottic cancer patients (p < 0.0001), and the odds were 1.68 ± 0.40 times higher in stage III-IV patients compared with stage I-II patients (p = 0.03). Seperate analyses revealed that tumor site and stage only predicted weight loss in patients with BMI >25 but not in patients with BMI <25. Patients receiving a feeding tube weighed less than patients without (73.8 vs 78.3 kg) and feeding tube reduced, but did not prevent, weight loss which averaged 6.7 ± 4.7 kg (7.4 ± 4.7 %) compared with 4.7 ± 5.9 kg (5.5 ± 6.0 %) in patients without a feeding tube (P < 0.0001).

Conclusion: Pre-treatment BMI, tumor site and stage predicted weight loss above 5 % in HNSCC patients during radiotherapy. BMI should be considered when analyzing weight loss in HNSCC patients receiving curative radiotherapy.

Citing Articles

Weight censorial score: estimation of the weight loss during concurrent chemo-radiotherapy in nasopharyngeal carcinoma patients by image features predicts prognosis.

Sun J, Lam S, Zhang J, Teng X, Lee F, Yip C Radiol Med. 2025; 130(3):381-396.

PMID: 39873917 PMC: 11903536. DOI: 10.1007/s11547-025-01953-9.

The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial.

Almassri H, Abdul Kadir A, Srour M, Foo L Nutrients. 2024; 16(22).

PMID: 39599746 PMC: 11597444. DOI: 10.3390/nu16223960.

Effect of nutrition impact symptoms on oral nutritional supplements energy intake and use days in patients with head and neck cancer: A cross-sectional study.

Dai T, Xian J, Li X, Wang Z, Hu W Cancer Med. 2024; 13(10):e7288.

PMID: 38770538 PMC: 11106646. DOI: 10.1002/cam4.7288.

Effectiveness of Comprehensive Intervention Programme on Quality of life, fatigue, self-efficacy, and psychosocial distress among head and neck cancer patients receiving radiotherapy.

Nayak S, George A, Sharan K, Nayak B, Ravishankar N Support Care Cancer. 2024; 32(4):216.

PMID: 38448712 PMC: 10917822. DOI: 10.1007/s00520-024-08381-x.

Predictive Factors for Critical Weight Loss in Saudi Head and Neck Cancer Patients Undergoing (Chemo)Radiotherapy.

Redwan A, Kattan F, Alidrisi M, Ali G, Ghaith M, Arbaeen A Cancers (Basel). 2024; 16(2).

PMID: 38254902 PMC: 10814742. DOI: 10.3390/cancers16020414.

References

Ottosson S, Zackrisson B, Kjellen E, Nilsson P, Laurell G . Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy. Acta Oncol. 2012; 52(4):711-8. PMC: 3622234. DOI: 10.3109/0284186X.2012.731524. View

Lonbro S, Dalgas U, Primdahl H, Johansen J, Nielsen J, Aagaard P . Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy--results from the randomized DAHANCA 25B trial. Radiother Oncol. 2013; 108(2):314-9. DOI: 10.1016/j.radonc.2013.07.002. View

Mortensen H, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen J . Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012; 103(1):69-75. DOI: 10.1016/j.radonc.2012.01.002. View

Langius J, van Dijk A, Doornaert P, Kruizenga H, Langendijk J, Leemans C . More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. Nutr Cancer. 2013; 65(1):76-83. DOI: 10.1080/01635581.2013.741749. View

Langius J, Zandbergen M, Eerenstein S, Van Tulder M, Leemans C, Kramer M . Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. Clin Nutr. 2013; 32(5):671-8. DOI: 10.1016/j.clnu.2013.06.012. View

Garg S, Yoo J, Winquist E . Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review. Support Care Cancer. 2009; 18(6):667-77. DOI: 10.1007/s00520-009-0686-3. View

Olson R, Karam I, Wilson G, Bowman A, Lee C, Wong F . Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?. Support Care Cancer. 2013; 21(12):3433-9. DOI: 10.1007/s00520-013-1936-y. View

Koyfman S, Adelstein D . Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. Int J Radiat Oncol Biol Phys. 2012; 84(3):581-9. DOI: 10.1016/j.ijrobp.2012.03.053. View

Cady J . Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs. 2007; 11(6):875-80. DOI: 10.1188/07.CJON.875-880. View

10.

Silander E, Nyman J, Hammerlid E . An exploration of factors predicting malnutrition in patients with advanced head and neck cancer. Laryngoscope. 2013; 123(10):2428-34. DOI: 10.1002/lary.23877. View

11.

Lassen P . The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol. 2010; 95(3):371-80. DOI: 10.1016/j.radonc.2010.04.022. View

12.

Zhao J, Zheng H, Li L, Zhang L, Zhao Y, Jiang N . Predictors for Weight Loss in Head and Neck Cancer Patients Undergoing Radiotherapy: A Systematic Review. Cancer Nurs. 2015; 38(6):E37-45. DOI: 10.1097/NCC.0000000000000231. View

13.

Pignon J, Le Maitre A, Maillard E, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1):4-14. DOI: 10.1016/j.radonc.2009.04.014. View

14.

Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100(1):33-40. DOI: 10.1016/j.radonc.2011.05.036. View

15.

Bentzen J, Toustrup K, Eriksen J, Primdahl H, Andersen L, Overgaard J . Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. 2015; 54(7):1001-7. DOI: 10.3109/0284186X.2014.992547. View

16.

Al-Mamgani A, van Rooij P, Woutersen D, Mehilal R, Tans L, Monserez D . Radiotherapy for T1-2N0 glottic cancer: a multivariate analysis of predictive factors for the long-term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients. Clin Otolaryngol. 2013; 38(4):306-12. DOI: 10.1111/coa.12139. View

17.

Overgaard J, Hansen H, Overgaard M, Bastholt L, BERTHELSEN A, Specht L . A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998; 46(2):135-46. DOI: 10.1016/s0167-8140(97)00220-x. View

18.

Metwally M, Frederiksen K, Overgaard J . Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2013; 53(5):654-61. DOI: 10.3109/0284186X.2013.864050. View

19.

Nourissat A, Bairati I, Samson E, Fortin A, Gelinas M, Nabid A . Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer. Cancer. 2010; 116(9):2275-83. DOI: 10.1002/cncr.25041. View

20.

Jager-Wittenaar H, Dijkstra P, Vissink A, Langendijk J, van der Laan B, Pruim J . Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Head Neck. 2010; 33(6):863-70. DOI: 10.1002/hed.21546. View